Olema Pharmaceuticals (OLMA)
(Delayed Data from NSDQ)
$4.64 USD
-0.08 (-1.69%)
Updated Aug 8, 2025 04:00 PM ET
After-Market: $4.63 -0.01 (-0.22%) 7:58 PM ET
4-Sell of 5 4
C Value D Growth A Momentum C VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
OLMA 4.64 -0.08(-1.69%)
Will OLMA be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for OLMA based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for OLMA
Wall Street Analysts See a 386.42% Upside in Olema Pharmaceuticals (OLMA): Can the Stock Really Move This High?
Wall Street Analysts Think Olema Pharmaceuticals (OLMA) Could Surge 433.13%: Read This Before Placing a Bet
OLMA: What are Zacks experts saying now?
Zacks Private Portfolio Services
After Plunging -30.16% in 4 Weeks, Here's Why the Trend Might Reverse for Olema Pharmaceuticals (OLMA)
Novartis' Gene Therapy Meets Primary Endpoint in SMA Study
Novartis Announces Positive Results From Late-Stage Study on Fabhalta
Other News for OLMA
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | OLMA Stock News
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | OLMA Stock News
Olema Pharmaceuticals Holds Annual Stockholders Meeting
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | OLMA Stock News
12 Health Care Stocks Moving In Monday's Intraday Session